Clinical Trial Update: Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®) [Phase 2]

View source ↗

Summary

Phase 2 trial update of irofulven in metastatic castration-resistant prostate cancer patients previously treated with docetaxel, using a Drug Response Predictor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Irofulven (irofulven)

Snippet

Sponsor: Allarity Therapeutics | Conditions: Metastatic Castration-Resistant Prostate Cancer Patients | Phase 2 | Status: COMPLETED